Comparative Pharmacokinetics of Two Different Oral Delivery Systems of Cholecalciferol

NCT ID: NCT05104970

Last Updated: 2022-05-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-09

Study Completion Date

2023-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to adapt the gold standard of research and to explore the comparative bioavailability and clinical efficacy of the two most commonly used forms of Cholecalciferol i.e. ampoules and softgel capsules.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Deficiency of Vitamin D is highly prevalent in all sectors and regions of Pakistan. Its effects encompass multiple pluripotent physiological impacts on human body, including its classical action on bone health and immune modulation. Health care workers are routinely prescribing supplementations to correct the deficiencies. Different forms of Cholecalciferol are available in the market. It ranges from absorba liquids, drops, tablets, softgels to injectable and oral ampoules. Different delivery systems offer different advantages, challenges and efficacies specific to their specific pharmacokinetics. The aim of this study is to adapt the gold standard of research and to explore the comparative bioavailability and clinical efficacy of the two most commonly used forms of Cholecalciferol i.e. ampoules and softgel capsules.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers
double blinded placebo controlled

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SunnyD STAT softgel capsule

Cholecalciferol 200000 IU

Group Type ACTIVE_COMPARATOR

SunnyD STAT softgel capsule

Intervention Type DIETARY_SUPPLEMENT

Cholecalciferol 200000 IU softgel capsule

Placebo SunnyD STAT softgel capsule

Olive oil only

Group Type PLACEBO_COMPARATOR

Placebo SunnyD STAT softgel capsule

Intervention Type DIETARY_SUPPLEMENT

Olive oil

SunnyD insta ampoule

Vitamin D3 200000 IU

Group Type ACTIVE_COMPARATOR

SunnyD insta ampoule

Intervention Type DRUG

Cholecalciferol 200000 IU insta ampoule

Placebo SunnyD insta ampoule

Olive oil only

Group Type PLACEBO_COMPARATOR

Placebo SunnyD insta ampoule

Intervention Type DRUG

Olive oil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SunnyD insta ampoule

Cholecalciferol 200000 IU insta ampoule

Intervention Type DRUG

SunnyD STAT softgel capsule

Cholecalciferol 200000 IU softgel capsule

Intervention Type DIETARY_SUPPLEMENT

Placebo SunnyD insta ampoule

Olive oil

Intervention Type DRUG

Placebo SunnyD STAT softgel capsule

Olive oil

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult (20-70 years of age)
2. Vitamin D deficiency (serum 25(OH)D \< 20 ng/ml)
3. Permanent employees of Medicine ward of Holy Family Hospital, DHQ, BBH hospitals and RMU for easy follow up throughout the study duration
4. Willingness and availability to show-up in the follow up visit and serum testing throughout the study period as needed

Exclusion Criteria

1. Vitamin D sufficiency or moderate deficiency (serum 25(OH)D \> 20 ng/ml)
2. Pregnant ladies
3. Participants already taking Vitamin D supplementation, anti-convulsants, barbiturates or steroids
4. Subjects with granulomatous conditions, liver disease, kidney disease, or diabetes
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rawalpindi Medical College

OTHER

Sponsor Role collaborator

Scotmann Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muhammad Umar, MBBS,FCPS

Role: PRINCIPAL_INVESTIGATOR

Rawalpindi Medical College

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Syeda Saba Aslam, MBBS, MPH

Role: CONTACT

00923136674333

Fazlur Rehman, MBBS,FCPS

Role: CONTACT

00923005226950

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SunnyD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.